Biologics, which appear to have a safer risk-to-benefit ratio compared to cyclosporine, have more or less supplanted this drug for psoriasis in most patients. Humira (adalimumab) is a commonly ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Psoriasis is a chronic skin disorder characterized ... Three other biologics — adalimumab (Humira; Abbott), etanercept (Enbrel; Amgen/Wyeth/Takeda) and infliximab (Remicade; Centocor Ortho ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...